POINT Biopharma Global is a radiopharmaceutical company focusing on the clinical development and commercialization of radioligands for cancer treatment. Co.'s product candidates include: PNT2002, which is a prostate-specific membrane antigen (PSMA) targeted radioligand for the treatment of metastatic castration-resistant prostate cancer; PNT2004, which is a fibroblast activation protein-a targeting program being developed for use in several tumor types; PNT2003, which is a somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors; and PNT2001, which is a PSMA targeting ligand family that utilizes linker technology that promotes increased tumor accumulation. We show 11 historical shares outstanding datapoints in our PNT shares outstanding history coverage, used to compute PNT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PNT market cap history over the course of time is important for investors
interested in comparing PNT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PNT versus a peer is one thing; comparing
PNT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PNT can fluctuate over the course of history.
With this page we aim to empower investors researching PNT by allowing them to research the PNT market cap history. |
Free PNT Email Alerts:
Video: The Importance of Market Cap
